Vivodyne Develops World's Largest Biological Datacenter to Enhance Drug Testing
Vivodyne has created a biological datacenter capable of conducting controlled experiments on over 3.1 million human tissues annually. This innovation addresses the high failure rate of drugs in clinical trials by allowing pharmaceutical companies to evaluate drug effects on living human tissues before human trials.
Theia Market Signal Identification - AI Assisted
Vivodyne's platform consists of 12 robotic laboratories, termed 'hives,' aiming to resolve the inefficiencies in pharmaceutical research, where 90% of drugs fail in clinical trials. The core technology is the TissueDisk Series 2, a biologically advanced chip that cultivates live human tissues, simulating organ functions.
Major pharmaceutical companies have already paid for early access to this technology, which could drastically reduce clinical trial failures. Additionally, the data generated will help train AI models to systematically understand human biology, enhancing future drug development. The company's biological datacenters are located in the Bay Area of San Francisco and Philadelphia, USA.
Comments